story of the week
Adjuvant Pertuzumab and Trastuzumab in Early HER2+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
N. Engl. J. Med 2017 Jun 05;[EPub Ahead of Print], G von Minckwitz, M Procter, E de Azambuja, D Zardavas, M Benyunes, G Viale, T Suter, A Arahmani, N Rouchet, E Clark, A Knott, I Lang, C Levy, DA Yardley, J Bines, RD Gelber, M Piccart, J BaselgaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.